Milrinone Zentiva

Milrinone, the active ingredient in Milrinone Zentiva, is a phosphodiesterase‑3 inhibitor presented as an injectable solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock in hospitalized patients. GNH USA supplies Milrinone Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Milrinone is used in cardiovascular emergencies where enhanced cardiac contractility and vasodilation are needed. - Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: supports systemic circulation while other therapies are initiated. - Post‑cardiac surgery low cardiac output syndrome: helps restore adequate perfusion during the early postoperative period.

Milrinone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Arrhythmias: premature ventricular contractions or tachycardia. - Hypotension: transient drop in blood pressure. - Flushing: warmth and redness of skin. - Thrombocytopenia: reduced platelet count.

Serious or Rare Side Effects: - Sustained ventricular tachyarrhythmias: potentially life‑threatening. - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, urticaria, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

Milrinone requires careful monitoring and specific safety measures before and during therapy. - Cardiac monitoring: continuous ECG and hemodynamic assessment. - Electrolyte balance: correct potassium and magnesium levels to reduce arrhythmia risk. - Renal function: adjust infusion rates in severe renal impairment. - Concomitant vasodilators: avoid excessive hypotension when combined with other vasodilators. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Concurrent use of other phosphodiesterase inhibitors: risk of profound hypotension. - High‑dose beta‑agonists: additive tachyarrhythmic potential.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances. - Anticoagulants: monitor for bleeding if thrombocytopenia occurs. - Nitrates: monitor blood pressure for additive vasodilatory effect.